Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression: Possible role of insulin-like growth factors and insulin-like growth factor-binding proteins

Giancarlo Torre, Antonina Barreca, Giacomo Borgonovo, Michele Minuto, Gian Luca Ansaldo, Emanuela Varaldo, Francesco Minuto

Research output: Contribution to journalArticle

Abstract

Background. It is known that factors other than thyroid-stimulating hormone, such as insulin-like growth factor-I (IGF-I) and epidermal growth factor, have a goitrogenic effect. It has been established that insulin-like growth factor-binding proteins (IGFBPs) may play a role as autocrine/paracrine factors in regulating the local actions of IGFs. Both an inhibitory and a stimulatory effect for different IGFBPs have been shown in several cell systems. The aim of this study was to assess the involvement of IGFBPs in the goitrogenic process in patients with goiter recurrence. Methods. The IGFBP-1 and -3 content in normal and nodular tissues obtained at the time of thyroidectomy from 10 patients with recurrent goiters, unresponsive to thyroid-stimulating hormone suppressive therapy, was studied. In all patients, a fragment of normal tissue was also obtained. The IGF-I, IGFBP-1, and -3 content was evaluated by specific immunoassays and/or immunoblotting with anti-IGFBP specific antiserum. Results. The IGF-I content was significantly higher (P <.05) in nodular tissues (8.0 ± 1.6 ng/g of tissue) than what was found in normal tissue (4.8 ± 0.9 ng/g). Radioimmunoassay IGFBP-3 concentration in nodular tissue was 111.5 ± 18.2 ng/g significantly higher (P <.001) than values found in normal tissue (77.5 ± 18.6 ng/g). By immunoblot, IGFBP-1 appeared higher in all but 1 nodular tissue. Conclusions. These data raise the possibility that IGFBPs are important in the proliferative activities entailed in the goitrogenic process. Three mechanisms are potentially involved: (1) reduction of the potency of locally produced IGF peptide to downregulate type I receptors (potentiating effect on the autocrine/paracrine mitogenic action of IGFs); (2) increase of the IGF-I tissue concentration restraining its passage to circulation; and (3) protection of IGF-I from degradation. Further studies are needed to define a more precise link between these factors and the recurrence of goiter.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalSurgery
Volume127
Issue number1
Publication statusPublished - 2000

Fingerprint

Insulin-Like Growth Factor Binding Proteins
Goiter
Somatomedins
Thyrotropin
Recurrence
Insulin-Like Growth Factor I
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 3
Thyroidectomy
Immunoassay
Immunoblotting
Epidermal Growth Factor
Radioimmunoassay
Immune Sera
Down-Regulation
Peptides

ASJC Scopus subject areas

  • Surgery

Cite this

Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression : Possible role of insulin-like growth factors and insulin-like growth factor-binding proteins. / Torre, Giancarlo; Barreca, Antonina; Borgonovo, Giacomo; Minuto, Michele; Ansaldo, Gian Luca; Varaldo, Emanuela; Minuto, Francesco.

In: Surgery, Vol. 127, No. 1, 2000, p. 99-103.

Research output: Contribution to journalArticle

Torre, G, Barreca, A, Borgonovo, G, Minuto, M, Ansaldo, GL, Varaldo, E & Minuto, F 2000, 'Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression: Possible role of insulin-like growth factors and insulin-like growth factor-binding proteins', Surgery, vol. 127, no. 1, pp. 99-103.
Torre, Giancarlo ; Barreca, Antonina ; Borgonovo, Giacomo ; Minuto, Michele ; Ansaldo, Gian Luca ; Varaldo, Emanuela ; Minuto, Francesco. / Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression : Possible role of insulin-like growth factors and insulin-like growth factor-binding proteins. In: Surgery. 2000 ; Vol. 127, No. 1. pp. 99-103.
@article{5667f080395d4d5aae5d3f47d67798fd,
title = "Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression: Possible role of insulin-like growth factors and insulin-like growth factor-binding proteins",
abstract = "Background. It is known that factors other than thyroid-stimulating hormone, such as insulin-like growth factor-I (IGF-I) and epidermal growth factor, have a goitrogenic effect. It has been established that insulin-like growth factor-binding proteins (IGFBPs) may play a role as autocrine/paracrine factors in regulating the local actions of IGFs. Both an inhibitory and a stimulatory effect for different IGFBPs have been shown in several cell systems. The aim of this study was to assess the involvement of IGFBPs in the goitrogenic process in patients with goiter recurrence. Methods. The IGFBP-1 and -3 content in normal and nodular tissues obtained at the time of thyroidectomy from 10 patients with recurrent goiters, unresponsive to thyroid-stimulating hormone suppressive therapy, was studied. In all patients, a fragment of normal tissue was also obtained. The IGF-I, IGFBP-1, and -3 content was evaluated by specific immunoassays and/or immunoblotting with anti-IGFBP specific antiserum. Results. The IGF-I content was significantly higher (P <.05) in nodular tissues (8.0 ± 1.6 ng/g of tissue) than what was found in normal tissue (4.8 ± 0.9 ng/g). Radioimmunoassay IGFBP-3 concentration in nodular tissue was 111.5 ± 18.2 ng/g significantly higher (P <.001) than values found in normal tissue (77.5 ± 18.6 ng/g). By immunoblot, IGFBP-1 appeared higher in all but 1 nodular tissue. Conclusions. These data raise the possibility that IGFBPs are important in the proliferative activities entailed in the goitrogenic process. Three mechanisms are potentially involved: (1) reduction of the potency of locally produced IGF peptide to downregulate type I receptors (potentiating effect on the autocrine/paracrine mitogenic action of IGFs); (2) increase of the IGF-I tissue concentration restraining its passage to circulation; and (3) protection of IGF-I from degradation. Further studies are needed to define a more precise link between these factors and the recurrence of goiter.",
author = "Giancarlo Torre and Antonina Barreca and Giacomo Borgonovo and Michele Minuto and Ansaldo, {Gian Luca} and Emanuela Varaldo and Francesco Minuto",
year = "2000",
language = "English",
volume = "127",
pages = "99--103",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression

T2 - Possible role of insulin-like growth factors and insulin-like growth factor-binding proteins

AU - Torre, Giancarlo

AU - Barreca, Antonina

AU - Borgonovo, Giacomo

AU - Minuto, Michele

AU - Ansaldo, Gian Luca

AU - Varaldo, Emanuela

AU - Minuto, Francesco

PY - 2000

Y1 - 2000

N2 - Background. It is known that factors other than thyroid-stimulating hormone, such as insulin-like growth factor-I (IGF-I) and epidermal growth factor, have a goitrogenic effect. It has been established that insulin-like growth factor-binding proteins (IGFBPs) may play a role as autocrine/paracrine factors in regulating the local actions of IGFs. Both an inhibitory and a stimulatory effect for different IGFBPs have been shown in several cell systems. The aim of this study was to assess the involvement of IGFBPs in the goitrogenic process in patients with goiter recurrence. Methods. The IGFBP-1 and -3 content in normal and nodular tissues obtained at the time of thyroidectomy from 10 patients with recurrent goiters, unresponsive to thyroid-stimulating hormone suppressive therapy, was studied. In all patients, a fragment of normal tissue was also obtained. The IGF-I, IGFBP-1, and -3 content was evaluated by specific immunoassays and/or immunoblotting with anti-IGFBP specific antiserum. Results. The IGF-I content was significantly higher (P <.05) in nodular tissues (8.0 ± 1.6 ng/g of tissue) than what was found in normal tissue (4.8 ± 0.9 ng/g). Radioimmunoassay IGFBP-3 concentration in nodular tissue was 111.5 ± 18.2 ng/g significantly higher (P <.001) than values found in normal tissue (77.5 ± 18.6 ng/g). By immunoblot, IGFBP-1 appeared higher in all but 1 nodular tissue. Conclusions. These data raise the possibility that IGFBPs are important in the proliferative activities entailed in the goitrogenic process. Three mechanisms are potentially involved: (1) reduction of the potency of locally produced IGF peptide to downregulate type I receptors (potentiating effect on the autocrine/paracrine mitogenic action of IGFs); (2) increase of the IGF-I tissue concentration restraining its passage to circulation; and (3) protection of IGF-I from degradation. Further studies are needed to define a more precise link between these factors and the recurrence of goiter.

AB - Background. It is known that factors other than thyroid-stimulating hormone, such as insulin-like growth factor-I (IGF-I) and epidermal growth factor, have a goitrogenic effect. It has been established that insulin-like growth factor-binding proteins (IGFBPs) may play a role as autocrine/paracrine factors in regulating the local actions of IGFs. Both an inhibitory and a stimulatory effect for different IGFBPs have been shown in several cell systems. The aim of this study was to assess the involvement of IGFBPs in the goitrogenic process in patients with goiter recurrence. Methods. The IGFBP-1 and -3 content in normal and nodular tissues obtained at the time of thyroidectomy from 10 patients with recurrent goiters, unresponsive to thyroid-stimulating hormone suppressive therapy, was studied. In all patients, a fragment of normal tissue was also obtained. The IGF-I, IGFBP-1, and -3 content was evaluated by specific immunoassays and/or immunoblotting with anti-IGFBP specific antiserum. Results. The IGF-I content was significantly higher (P <.05) in nodular tissues (8.0 ± 1.6 ng/g of tissue) than what was found in normal tissue (4.8 ± 0.9 ng/g). Radioimmunoassay IGFBP-3 concentration in nodular tissue was 111.5 ± 18.2 ng/g significantly higher (P <.001) than values found in normal tissue (77.5 ± 18.6 ng/g). By immunoblot, IGFBP-1 appeared higher in all but 1 nodular tissue. Conclusions. These data raise the possibility that IGFBPs are important in the proliferative activities entailed in the goitrogenic process. Three mechanisms are potentially involved: (1) reduction of the potency of locally produced IGF peptide to downregulate type I receptors (potentiating effect on the autocrine/paracrine mitogenic action of IGFs); (2) increase of the IGF-I tissue concentration restraining its passage to circulation; and (3) protection of IGF-I from degradation. Further studies are needed to define a more precise link between these factors and the recurrence of goiter.

UR - http://www.scopus.com/inward/record.url?scp=0033979814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033979814&partnerID=8YFLogxK

M3 - Article

C2 - 10660765

AN - SCOPUS:0033979814

VL - 127

SP - 99

EP - 103

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 1

ER -